Inventiva (IVA) Stock Price, News & Analysis

Company Overview

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Key Stats

• Today's Range: $5.50 to $6.50
• 50-Day Range: $2.98 to $5.23
• 52-Week Range: $1.53 to $6.50
• Volume: 226,214 shs
• Average Volume: 19,868 shs
• Market Capitalization: $608.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Moderate Buy

Inventiva Stock Analysis - MarketRank™

Inventiva scored higher than 64% of companies evaluated by MarketBeat, and ranked 380th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Inventiva has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Inventiva has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inventiva are expected to grow in the coming year, from ($2.08) to ($1.85) per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Inventiva has been sold short.

Short Interest Ratio / Days to Cover

Inventiva has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inventiva has recently decreased by 72.90%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inventiva does not currently pay a dividend.

Dividend Growth

Inventiva does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the float of Inventiva has been sold short.

Short Interest Ratio / Days to Cover

Inventiva has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Inventiva has recently decreased by 72.90%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.36

News Sentiment

Inventiva has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Inventiva this week, compared to 2 articles on an average week.

Search Interest

5 people have searched for IVA on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Inventiva to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inventiva insiders have not sold or bought any company stock.

Percentage Held by Insiders

32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 19.06% of the stock of Inventiva is held by institutions.

IVA Stock Analysis - Frequently Asked Questions

How have IVA shares performed this year?

Inventiva's stock was trading at $2.14 on January 1st, 2025. Since then, IVA shares have increased by 194.9% and is now trading at $6.31.

When did Inventiva IPO?

Inventiva (IVA) raised $103 million in an initial public offering on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

Who are Inventiva's major shareholders?

Inventiva's top institutional shareholders include Wealth Enhancement Advisory Services LLC (0.02%) and Creative Planning (0.01%).

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inventiva own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inventiva investors own include Kinross Gold (KGC), Oncobiologics (OTLK), Accuray (ARAY), Carnival (CCL), Alibaba Group (BABA), PayPal (PYPL).

Company Calendar

• Today: 8/28/2025
• Next Earnings (Estimated): 9/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IVA
• CIK: 1756594
• Web: www.inventivapharma.com
• Phone: 33-3-80-44-75-00
• Fax: N/A
• Employees: 100
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Inventiva: $13.00
• High Price Target: $26.00
• Low Price Target: $3.00
• Potential Upside/Downside: +148.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.92
• Quick Ratio: 0.92

Sales & Book Value

• Annual Sales: $9.95 million
• Price / Sales: 50.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.21) per share
• Price / Book: -4.32

Miscellaneous

• Outstanding Shares: 95,660,000
• Free Float: 65,050,000
• Market Cap: $500.30 million
• Optionable: Not Optionable
• Beta: 0.73